Welcome to our dedicated page for FENNEC PHARMACEUTICALS SEC filings (Ticker: FENC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fennec Pharmaceuticals Inc. filings document formal disclosures for its commercial specialty pharmaceutical business, PEDMARK® product updates, and Nasdaq-listed common shares. Recent Form 8-K reports cover financial results, scientific presentations and investigator-sponsored studies involving sodium thiosulfate injection, and a license agreement resolving litigation tied to a proposed generic version of PEDMARK.
The company’s proxy materials cover director elections, board composition, executive compensation, equity awards, and shareholder voting matters. Other current reports disclose governance changes, registered common shares with no par value, and exhibits furnished with press releases concerning business, clinical, and product-related developments.
Fennec Pharmaceuticals (FENC) reported an insider transaction on a Form 4. Director Rosty Raykov sold 10,000 common shares on 11/05/2025 at $8.10 per share in an open-market sale. Following the transaction, he beneficially owns 82,318 shares, held directly.
The sale was made pursuant to a Rule 10b5-1 trading plan dated August 23, 2024, indicating pre‑arranged trading parameters.
Fennec Pharmaceuticals (FENC) reported an insider equity change. Director Rosty Raykov acquired 5,208 common shares on 10/31/2025 at $0, reflecting the release of restricted shares previously awarded on 3/31/2023 and 5/16/2024. Following this transaction, Raykov beneficially owns 92,318 shares, held directly.
The filing lists no derivative transactions in Table II.
Fennec Pharmaceuticals (FENC) Form 4: Chief Financial Officer Robert Andrade reported acquiring 2,430 common shares at $0 on 10/31/2025. The filing states these shares were released from restriction related to awards granted on 3/31/2023 and 5/16/2024. Following the transaction, Andrade beneficially owns 173,104 shares, held directly.
Fennec Pharmaceuticals (FENC) reported an insider transaction by a director on 10/10/2025. The director exercised 4,062 options at a $1.23 exercise price under a 10b5-1 plan adopted on May 19, 2025, acquiring the same number of common shares. To cover taxes from the exercise, the insider sold 1,775 shares at $9.24. Following these transactions, the insider beneficially owned 57,079 common shares directly and held 174,344 derivative securities (options) after the reported activity.
Fennec Pharmaceuticals (FENC) filed a Form 144 notifying a proposed sale of 1,775 common shares with an aggregate market value of $16,401.00. The shares are scheduled for sale approximately on 10/10/2025 on NASDAQ. The filing shows the shares were acquired the same day, 10/10/2025, by stock option exercise from the issuer and paid in cash. There were 27,831,698 shares outstanding noted for the class. No securities were reported sold in the prior three months. The filer affirms they are not aware of undisclosed material adverse information and the notice contains the standard attestation language regarding trading plans and criminal penalties for false statements.
Fennec Pharmaceuticals (FENC) insiders filed a Form 4 reporting multiple open-market sales of common stock across 10/07/2025 to 10/09/2025
Reporting entities tied to Southpoint (Southpoint Capital Advisors LP/LLC, Southpoint GP entities and John S. Clark II) sold a total of 67,114 shares in three tranches at weighted-average prices of approximately $9.5871, $9.4732, and $9.3461. Reported beneficial ownership after each trade was 4,050,314, 4,030,709, and 4,010,100 shares respectively. The filing explains that the shares are held directly by Southpoint Master Fund, LP and that the reporting persons disclaim beneficial ownership except for pecuniary interest.
Insider exercised options to buy 4,609 common shares at $2.45, increasing direct beneficial ownership to 87,110 shares. The transaction was executed on 10/08/2025 via exercise of stock options that carry a $2.45 strike and expire on 07/05/2026. After the exercise the reporting person holds 4,609 underlying options shown as exercised and 1,634,184 remaining outstanding options in the same class per the filing table. The form is a Section 16 filing by a director, showing a routine option exercise rather than a market sale or open-market purchase.
Insider sale by director: A director, Rosty Raykov, reported the sale of 10,000 common shares of FENNEC PHARMACEUTICALS INC. (FENC) on 10/06/2025 at a price of $9.78 per share. The filing states the shares were sold under a 10b5-1 plan dated 08/23/2024, indicating the transactions were pre-planned. After the sale, the reporting person beneficially owns 82,501 shares, held directly. The form is a standard Section 16 disclosure by a company director and does not include other derivative transactions.
Fennec Pharmaceuticals, Inc. (FENC) reported a proposed insider sale under Rule 144: 10,000 common shares planned for 10/06/2025 through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $97,868. The issuer shows 27,831,698 shares outstanding, so the proposed sale equals approximately 0.036 of outstanding shares.
The filer acquired the 10,000 shares as restricted stock in three tranches on 05/16/2025 (5,485 shares), 05/31/2025 (2,085), and 09/30/2025 (2,430), all issued by the company. The notice also discloses two prior sales by the same person in the past three months: 10,000 shares sold on 09/04/2025 for $89,220 and 10,000 shares sold on 08/05/2025 for $80,933. The filer attests not to possess undisclosed material adverse information.
Rosty Raykov, a director of Fennec Pharmaceuticals Inc. (FENC), reported a non‑derivative acquisition of 5,208 common shares on 09/30/2025 at a reported price of $0. The filing states these shares were released from restrictions tied to awards granted on 03/31/2023 and 05/16/2024. After the release, Mr. Raykov beneficially owns 92,501 shares of common stock. The Form 4 was filed by one reporting person and lists Mr. Raykov’s relationship to the issuer as a director. The transaction appears to be the routine vesting or release of previously awarded restricted stock rather than an open‑market purchase or sale.